Related Experiment Video
Updated: Feb 24, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult
John Gardner1, Andrew Webster2
1School of Social Sciences, Monash University, Clayton, Melbourne, Victoria, Australia.
Abstract:
The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to "accelerate" innovation. This article examines in detail one such agency, the United Kingdom's Cell and Gene Therapy Catapult (CGTC). We describe CGTC's role as an accelerator agency and its value narrative, which combines both "health and wealth." Drawing on the notion of sociotechnical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Gene Therapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
Plant Breeding and Biotechnology
Biopharmaceutical Factors Influencing Drug Product Design: Overview

